Annual Report on the External Quality Assessment Scheme for Tumor Markers in Korea (2017).
10.15263/jlmqa.2018.40.2.70
- Author:
Sang Hoon SONG
1
Author Information
1. Department of Laboratory Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. cloak21@snu.ac.kr
- Publication Type:Review
- Keywords:
Proficiency testing;
Tumor marker;
Korean Association of External Quality Assessment Service
- MeSH:
alpha-Fetoproteins;
Biomarkers, Tumor*;
Carcinoembryonic Antigen;
Korea*;
Prostate-Specific Antigen;
Vitamin K
- From:Journal of Laboratory Medicine and Quality Assurance
2018;40(2):70-76
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
In 2017, the tumor marker program of the Korean Association of External Quality Assessment Service was performed for tumor markers I and II. Tumor marker I comprised alpha-fetoprotein (AFP), carcinoembryonic antigen, protein induced by vitamin K absence-II, and prostate specific antigen (PSA), and tumor marker II comprised cancer antigen (CA) 125, CA 19-9, CA 15-3, CA 72-4, and beta-2-microglobulin. Two challenges were conducted with three pooled serum or control materials, except for the first tumor marker I challenge. In total, 648 institutions participated in tumor marker I and 380 in tumor marker II programs. The response rates were 92.9%–97.0%. The coefficients of variation (CVs) were different depending on tests and samples, and average CVs were 3.7%–16.8%. The average CV of CA 72-4 tests, whose number of participants was the smallest, was the lowest. The average CV of AFP tests, which included a sample with very high levels, was the highest.
